Direct anterior vs. posterior approach in hip arthroplasty: A systematic review and meta-analysis for Asian demographics

髋关节置换术中直接前入路与后入路:针对亚洲人群的系统评价和荟萃分析

阅读:1

Abstract

BACKGROUND: The Direct Anterior Approach (DAA) in Total Hip Arthroplasty (THA) is gaining popularity due to faster recovery and lower dislocation rates than the Posterior Approach (PA). However, its adoption in Asia remains limited. This systematic review compares functional, radiological, and clinical outcomes of DAA and PA in Asian populations. METHODS: A systematic search was conducted in PubMed, Embase, Cochrane Library, Google Scholar, and regional databases (up to September 2024). Comparative studies (RCTs, cohort studies) on DAA vs. PA in Asian adults were included. The risk of bias was assessed using the Cochrane Risk of Bias 2 tool for RCTs and the Newcastle-Ottawa Scale for cohort studies. Meta-analysis was performed using RevMan 5.3, applying fixed or random-effects models based on heterogeneity (I(2) > 50 %). RESULTS: Eight studies (1 RCT, 7 cohort studies) with 886 patients (DAA: 451, PA: 435) were included. Most studies were from China (4), Japan (2), India (1), and Singapore (1). Meta-analysis showed shorter hospital stays with DAA (MD: -2.38 days, 95 % CI: -3.69 to -1.07, p = 0.0004), with no significant differences in operative time and blood loss. Radiological outcomes were similar. DAA had better early functional outcomes (1-3 months) but showed no long-term differences. DAA was associated with a higher risk of nerve injury. CONCLUSION: DAA and PA yield comparable functional and clinical outcomes in the Asian population. Although concerns about the learning curve have limited DAA adoption, structured training can mitigate these challenges. Given its increasing global acceptance, DAA is a viable alternative for THA in Asia. PROSPERO REGISTRATION NUMBER: CRD42024598643.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。